Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
株式のランク #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
株価
$64.97
最終同期: 2024-05-20
時価総額
$1.97B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Alpine Immune Sciences, Inc. (ALPN)

カテゴリー

Alpine Immune Sciences, Inc.(ALPN)の利益
Mar 2024 時点の利益 TTM: $-36.73M
Alpine Immune Sciences, Inc. の最新の財務報告によると、同社の現在の利益は $-36.73M です。2022 年には $-55.43M の利益を上げ、これは 2021 年の利益 $-50.42M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Alpine Immune Sciences, Inc. の利益の推移(2012 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-36.73M 14.50%
2023 $-32.08M -42.13%
2022 $-55.43M 9.94%
2021 $-50.42M 80.42%
2020 $-27.95M -33.23%
2019 $-41.85M 13.56%
2018 $-36.85M 361.64%
2017 $-7.98M -74.63%
2016 $-31.46M 37.89%
2015 $-22.82M 51.76%
2014 $-15.04M -7.17%
2013 $-16.20M 69.21%
2012 $-9.57M 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -14,460.11%
US
$1.95B -5,410.35%
NL
$-4.02B 10,833.48%
AU
$-3.09B 8,303.89%
US
- -
CH